PRLD - Prelude Therapeutics Inc
IEX Last Trade
1.375
0.065 4.727%
Share volume: 1,881
Last Updated: Thu 26 Dec 2024 04:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$1.31
0.07
4.96%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-8.46%
1 Month
23.42%
3 Months
-42.79%
6 Months
-68.60%
1 Year
-71.73%
2 Year
-74.19%
Key data
Stock price
$1.38
DAY RANGE
$1.29 - $1.36
52 WEEK RANGE
$0.91 - $6.80
52 WEEK CHANGE
-$70.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Krishna Vaddi
Region: US
Website: preludetx.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: preludetx.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Prelude Therapeutics Incorporated focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Recent news